Report Detail
Global Duchenne Muscular Dystrophy Therapeutics Market Size, Status and Forecast 2019-2025
- RnM3463140 |
- 08 July, 2019 |
- Global |
- 91 Pages |
- QYResearch |
- Other
Duchenne muscular dystrophy (DMD) therapeutics helps treat genetic disorder caused due to absence of dystrophin, a protein in the body. The symptoms of the disease include weakness in the muscles of the hips, pelvic area, thighs, and shoulders, and later in the muscles of arms, legs, and trunk.
Factors such as, increase in incidences of Duchenne muscular dystrophy and introduction of specific guidance for development for Duchenne muscular dystrophy drugs by FDA drive the market growth. However, fast track approval of these drugs by FDA and untapped growth opportunities in the emerging economies of Asia-Pacific and LAMEA are expected to fuel the market growth during the forecast period.
In 2018, the global Duchenne Muscular Dystrophy Therapeutics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Duchenne Muscular Dystrophy Therapeutics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Duchenne Muscular Dystrophy Therapeutics development in United States, Europe and China.
The key players covered in this study
Bristol-Myers Squibb
FibroGen (U.S.)
Italfarmaco (Italy)
Marathon
NS Pharma (U.S.)
PTC Therapeutics (U.S.)
Pfizer
ReveraGen BioPharma (U.S.)
Santhera Pharmaceuticals (Switzerland)
Sarepta Therapeutics (U.S.)
Market segment by Type, the product can be split into
Pain Management Drugs
Corticosteroids
Prednisolone
Prednisone
Deflazacort
Market segment by Application, split into
Hospitals
Clinics
Home Care Settings
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Duchenne Muscular Dystrophy Therapeutics status, future forecast, growth opportunity, key market and key players.
To present the Duchenne Muscular Dystrophy Therapeutics development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Duchenne Muscular Dystrophy Therapeutics are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Key Market Segments
- 1.3 Players Covered
- 1.4 Market Analysis by Type
- 1.4.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size Growth Rate by Type (2014-2025)
- 1.4.2 Pain Management Drugs
- 1.4.3 Corticosteroids
- 1.4.4 Prednisolone
- 1.4.5 Prednisone
- 1.4.6 Deflazacort
- 1.5 Market by Application
- 1.5.1 Global Duchenne Muscular Dystrophy Therapeutics Market Share by Application (2014-2025)
- 1.5.2 Hospitals
- 1.5.3 Clinics
- 1.5.4 Home Care Settings
- 1.6 Study Objectives
- 1.7 Years Considered
2 Global Growth Trends
- 2.1 Duchenne Muscular Dystrophy Therapeutics Market Size
- 2.2 Duchenne Muscular Dystrophy Therapeutics Growth Trends by Regions
- 2.2.1 Duchenne Muscular Dystrophy Therapeutics Market Size by Regions (2014-2025)
- 2.2.2 Duchenne Muscular Dystrophy Therapeutics Market Share by Regions (2014-2019)
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
- 2.3.3 Market Opportunities
3 Market Share by Key Players
- 3.1 Duchenne Muscular Dystrophy Therapeutics Market Size by Manufacturers
- 3.1.1 Global Duchenne Muscular Dystrophy Therapeutics Revenue by Manufacturers (2014-2019)
- 3.1.2 Global Duchenne Muscular Dystrophy Therapeutics Revenue Market Share by Manufacturers (2014-2019)
- 3.1.3 Global Duchenne Muscular Dystrophy Therapeutics Market Concentration Ratio (CR5 and HHI)
- 3.2 Duchenne Muscular Dystrophy Therapeutics Key Players Head office and Area Served
- 3.3 Key Players Duchenne Muscular Dystrophy Therapeutics Product/Solution/Service
- 3.4 Date of Enter into Duchenne Muscular Dystrophy Therapeutics Market
- 3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
- 4.1 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Type (2014-2019)
- 4.2 Global Duchenne Muscular Dystrophy Therapeutics Market Size by Application (2014-2019)
5 United States
- 5.1 United States Duchenne Muscular Dystrophy Therapeutics Market Size (2014-2019)
- 5.2 Duchenne Muscular Dystrophy Therapeutics Key Players in United States
- 5.3 United States Duchenne Muscular Dystrophy Therapeutics Market Size by Type
- 5.4 United States Duchenne Muscular Dystrophy Therapeutics Market Size by Application
6 Europe
- 6.1 Europe Duchenne Muscular Dystrophy Therapeutics Market Size (2014-2019)
- 6.2 Duchenne Muscular Dystrophy Therapeutics Key Players in Europe
- 6.3 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Type
- 6.4 Europe Duchenne Muscular Dystrophy Therapeutics Market Size by Application
7 China
- 7.1 China Duchenne Muscular Dystrophy Therapeutics Market Size (2014-2019)
- 7.2 Duchenne Muscular Dystrophy Therapeutics Key Players in China
- 7.3 China Duchenne Muscular Dystrophy Therapeutics Market Size by Type
- 7.4 China Duchenne Muscular Dystrophy Therapeutics Market Size by Application
8 Japan
- 8.1 Japan Duchenne Muscular Dystrophy Therapeutics Market Size (2014-2019)
- 8.2 Duchenne Muscular Dystrophy Therapeutics Key Players in Japan
- 8.3 Japan Duchenne Muscular Dystrophy Therapeutics Market Size by Type
- 8.4 Japan Duchenne Muscular Dystrophy Therapeutics Market Size by Application
9 Southeast Asia
- 9.1 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size (2014-2019)
- 9.2 Duchenne Muscular Dystrophy Therapeutics Key Players in Southeast Asia
- 9.3 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size by Type
- 9.4 Southeast Asia Duchenne Muscular Dystrophy Therapeutics Market Size by Application
10 India
- 10.1 India Duchenne Muscular Dystrophy Therapeutics Market Size (2014-2019)
- 10.2 Duchenne Muscular Dystrophy Therapeutics Key Players in India
- 10.3 India Duchenne Muscular Dystrophy Therapeutics Market Size by Type
- 10.4 India Duchenne Muscular Dystrophy Therapeutics Market Size by Application
11 Central & South America
- 11.1 Central & South America Duchenne Muscular Dystrophy Therapeutics Market Size (2014-2019)
- 11.2 Duchenne Muscular Dystrophy Therapeutics Key Players in Central & South America
- 11.3 Central & South America Duchenne Muscular Dystrophy Therapeutics Market Size by Type
- 11.4 Central & South America Duchenne Muscular Dystrophy Therapeutics Market Size by Application
12 International Players Profiles
- 12.1 Bristol-Myers Squibb
- 12.1.1 Bristol-Myers Squibb Company Details
- 12.1.2 Company Description and Business Overview
- 12.1.3 Duchenne Muscular Dystrophy Therapeutics Introduction
- 12.1.4 Bristol-Myers Squibb Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
- 12.1.5 Bristol-Myers Squibb Recent Development
- 12.2 FibroGen (U.S.)
- 12.2.1 FibroGen (U.S.) Company Details
- 12.2.2 Company Description and Business Overview
- 12.2.3 Duchenne Muscular Dystrophy Therapeutics Introduction
- 12.2.4 FibroGen (U.S.) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
- 12.2.5 FibroGen (U.S.) Recent Development
- 12.3 Italfarmaco (Italy)
- 12.3.1 Italfarmaco (Italy) Company Details
- 12.3.2 Company Description and Business Overview
- 12.3.3 Duchenne Muscular Dystrophy Therapeutics Introduction
- 12.3.4 Italfarmaco (Italy) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
- 12.3.5 Italfarmaco (Italy) Recent Development
- 12.4 Marathon
- 12.4.1 Marathon Company Details
- 12.4.2 Company Description and Business Overview
- 12.4.3 Duchenne Muscular Dystrophy Therapeutics Introduction
- 12.4.4 Marathon Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
- 12.4.5 Marathon Recent Development
- 12.5 NS Pharma (U.S.)
- 12.5.1 NS Pharma (U.S.) Company Details
- 12.5.2 Company Description and Business Overview
- 12.5.3 Duchenne Muscular Dystrophy Therapeutics Introduction
- 12.5.4 NS Pharma (U.S.) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
- 12.5.5 NS Pharma (U.S.) Recent Development
- 12.6 PTC Therapeutics (U.S.)
- 12.6.1 PTC Therapeutics (U.S.) Company Details
- 12.6.2 Company Description and Business Overview
- 12.6.3 Duchenne Muscular Dystrophy Therapeutics Introduction
- 12.6.4 PTC Therapeutics (U.S.) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
- 12.6.5 PTC Therapeutics (U.S.) Recent Development
- 12.7 Pfizer
- 12.7.1 Pfizer Company Details
- 12.7.2 Company Description and Business Overview
- 12.7.3 Duchenne Muscular Dystrophy Therapeutics Introduction
- 12.7.4 Pfizer Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
- 12.7.5 Pfizer Recent Development
- 12.8 ReveraGen BioPharma (U.S.)
- 12.8.1 ReveraGen BioPharma (U.S.) Company Details
- 12.8.2 Company Description and Business Overview
- 12.8.3 Duchenne Muscular Dystrophy Therapeutics Introduction
- 12.8.4 ReveraGen BioPharma (U.S.) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
- 12.8.5 ReveraGen BioPharma (U.S.) Recent Development
- 12.9 Santhera Pharmaceuticals (Switzerland)
- 12.9.1 Santhera Pharmaceuticals (Switzerland) Company Details
- 12.9.2 Company Description and Business Overview
- 12.9.3 Duchenne Muscular Dystrophy Therapeutics Introduction
- 12.9.4 Santhera Pharmaceuticals (Switzerland) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
- 12.9.5 Santhera Pharmaceuticals (Switzerland) Recent Development
- 12.10 Sarepta Therapeutics (U.S.)
- 12.10.1 Sarepta Therapeutics (U.S.) Company Details
- 12.10.2 Company Description and Business Overview
- 12.10.3 Duchenne Muscular Dystrophy Therapeutics Introduction
- 12.10.4 Sarepta Therapeutics (U.S.) Revenue in Duchenne Muscular Dystrophy Therapeutics Business (2014-2019)
- 12.10.5 Sarepta Therapeutics (U.S.) Recent Development
13 Market Forecast 2019-2025
- 13.1 Market Size Forecast by Regions
- 13.2 United States
- 13.3 Europe
- 13.4 China
- 13.5 Japan
- 13.6 Southeast Asia
- 13.7 India
- 13.8 Central & South America
- 13.9 Market Size Forecast by Product (2019-2025)
- 13.10 Market Size Forecast by Application (2019-2025)
14 Analyst's Viewpoints/Conclusions
15 Appendix
- 15.1 Research Methodology
- 15.1.1 Methodology/Research Approach
- 15.1.1.1 Research Programs/Design
- 15.1.1.2 Market Size Estimation
- 12.1.1.3 Market Breakdown and Data Triangulation
- 15.1.2 Data Source
- 15.1.2.1 Secondary Sources
- 15.1.2.2 Primary Sources
- 15.1.1 Methodology/Research Approach
- 15.2 Disclaimer
Summary:
Get latest Market Research Reports on Duchenne Muscular Dystrophy Therapeutics . Industry analysis & Market Report on Duchenne Muscular Dystrophy Therapeutics is a syndicated market report, published as Global Duchenne Muscular Dystrophy Therapeutics Market Size, Status and Forecast 2019-2025. It is complete Research Study and Industry Analysis of Duchenne Muscular Dystrophy Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
